Churiwala Securities Pvt. Ltd. - leading and respected retail broking in India with over 3 decades of experience in creating wealth for investors with expertise in personalised investment planning in Equities / Portfolio Advisory for HNI & Retail clients.

Your results on : Equity | Corporate Action | Board Meetings

BSE Code

Company

Date

Purpose


500150	Foseco India	25-Feb-2026	Foseco India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/02/2026 ,inter alia, to consider and approve i) the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended December 31, 2025, and ii) to consider, if thought fit, to recommend the final dividend for the financial year ended December 31, 2025. and the Trading Window for dealing in the securities of the Company that had remained closed from January 1, 2026 shall continue to remain closed until February 27, 2026 (both days inclusive).

500249	KSB	25-Feb-2026	KSB Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/02/2026 inter alia to consider and approve the Standalone and Consolidated Audited Financial Results for the quarter and year ended 31st December 2025 and to consider the recommendation of Final Dividend on equity shares of the Company for the Financial Year 2025.

500295	Vedanta	25-Feb-2026	Inter alia, to consider the proposal for issuance of Non-Convertible Debentures on a private placement basis as part of its routine refinancing that is undertaken in ordinary course of business. The above issuance is pursuant to the Board of Directors' resolution passed at its meeting held on January 31, 2025.

500298	Naperol Invest.	25-Feb-2026	Naperol Investments Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/02/2026 inter alia to consider and approve the declaration of an interim dividend if any for the financial year 2025-26 Intimation for Closure of Trading Window is enclosed. The Board in its meeting to be held on February 25, 2026, to consider the declaration of interim dividend, if any, for FY 2025-26.

500674	Sanofi India	25-Feb-2026	Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/02/2026 inter alia to consider and approve the Audited Financial Results and Statements for the Quarter and Financial Year ended 31st December 2025 and Recommendation of Final Dividend if any.

508954	Finkurve Fin.	25-Feb-2026	Inter alia, to Consider and approve the raising of funds by issuance of 12% Non-Convertible Debentures having face value of Rs. 1,00,000 (Indian Rupees One Lakh only) each and issue price of Rs. 1,00,000 (Indian Rupees One Lakh only) through private placement via Electronic Bidding Platform (EBP).

526841	Shakti Press	25-Feb-2026	Inter alia, to consider and approve:- 1. The brief term of Rights Issue including Equity shares to be offered through the issue, issue price per equity share, Right entitlement ratio, Terms of Payment, etc. 2. Record date, timing of the Rights Issue and other matters incidental or connected therewith.

531099	Checkpoint Trend	25-Feb-2026	Inter-alia to consider and approve the following: 1. Resignation of Mr. Kumar Anubhav Upadhyay (DIN: 09519842), as Whole-Time Director of the Company. 2. Appointment of Mr. Anuj Kumar Agarwal (DIN: 08572887) as Whole-Time Director of the Company, subject to the approval of the Members of the Company. 3. Acquisition of Company. 4. Approval of Related Party Transaction.

531400	Almondz Global	25-Feb-2026	Almondz Global Securities Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/02/2026 inter alia to consider and approve We wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday 25th February 2026 inter alia to consider and evaluate proposal for raising of funds by way of a preferential issue in accordance with the provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations 2018 as amended and other applicable laws subject to requisite approvals including shareholders and statutory approvals. The aforesaid proposal may inter alia include conversion of outstanding loans into equity shares/ warrants and/or fresh issuance of equity shares/warrants or other eligible securities on a preferential basis subject to such regulatory/statutory approvals as may be required including approval of the shareholders of the Company.

531502	Esaar (India)	25-Feb-2026	Inter-alia to transact the following businesses as under: 1. To increase Authorized Share Capital of the Company and to make consequent alteration in clause V of Memorandum of Association. 2. Proposal for raising of funds by issuance of equity shares / convertible bonds / debentures / convertible warrants / preference shares or any other equity linked securities ("Securities") through permissible modes including by way of a rights issue, private placement, including through a preferential issue or qualified institutions placement of Securities or any other method or mode as may be permitted under applicable laws, including the Companies Act, 2013 read with the rules notified thereunder and the Securities and Exchange Board of India (issue of Capital and Disclosure Requirements) Regulations, 2018. 3. Any other items with the permission of chairperson. Esaar India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/02/2026 ,inter alia, to consider and approve Proposal for Raising of funds and Increase Authorized Share Capital of the Company and to make consequent alteration in clause V of Memorandum of Association .

<< < 1 2 > >>